Market Research Logo

EpiCast Report: Crohn’s Disease - Epidemiology Forecast to 2026

EpiCast Report: Crohn’s Disease - Epidemiology Forecast to 2026

Summary

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel.

Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 at an Annual Growth Rate (AGR) of 0.53%. The US will have the highest number of diagnosed incident cases of CD in both 2016 and 2026 at 44,886 and 47,477, respectively.

Our epidemiologists forecast that the diagnosed prevalent cases of CD in the 7MM will increase from 1,621,866 in 2016 to 1,961,224 in 2026 at an AGR of 2.09%. The US will have the highest number of diagnosed prevalent cases of CD in both 2016 and 2026; however, France will have the highest AGR at 4.04%.

The report EpiCast Report: Crohn’s Disease - Epidemiology Forecast to 2026, provides an overview of the risk factors, comorbidities, and global and historical trends for CD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of CD in these markets. The diagnosed prevalent cases of CD are further segmented by sex and age in these markets. The diagnosed prevalent cases are further segmented by severity (mild to moderate, moderate to severe, and severe to fulminant) and by comorbid autoimmune diseases (psoriasis, ankylosing spondylitis, and pyodermagangrenosum).

Furthermore, an alternate forecast of diagnosed incident and diagnosed prevalent cases of CD is provided for markets where there was insufficient data to trend in the main forecast, to estimate the patient size if trending was applied. For incident cases the alternate forecast includes the US and 5EU (France, Germany, Italy, Spain, and UK), and for prevalent cases the alternate forecast includes Germany, Italy, Spain, and the UK.

Scope

  • The Crohn’s Disease (CD) EpiCast Report provides an overview of the risk factors and global trends for CD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of CD in these markets. The diagnosed prevalent cases of CD are further segmented by sex and age in these markets. The diagnosed prevalent cases are further segmented by severity (mild to moderate, moderate to severe, and severe to fulminant) and by comorbid autoimmune diseases (psoriasis, ankylosing spondylitis, and pyoderma gangrenosum). Furthermore, an alternate forecast of diagnosed incident and diagnosed prevalent cases of CD is provided for markets where there was insufficient data to trend in the main forecast, to estimate the patient size if trending was applied.
  • The CD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The CD EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global CD market.
  • Quantify patient populations in the global CD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CD therapeutics in each of the markets covered.
  • Understand magnitude of CD population by disease severity and comorbid autoimmune diseases.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Crohn’s Disease: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Crohn’s Disease (2016-2026)
3.5.1 Diagnosed Incident Cases of Crohn’s Disease
3.5.2 Diagnosed Prevalent Cases of Crohn’s Disease
3.5.3 Age-Specific Diagnosed Prevalent Cases of Crohn’s Disease
3.5.4 Sex-Specific Diagnosed Prevalent Cases of Crohn’s Disease
3.5.5 Diagnosed Prevalent Cases of Crohn’s Disease by Severity
3.5.6 Diagnosed Prevalent Cases of Crohn’s Disease with Comorbid Autoimmune Diseases
3.6 Alternate Epidemiological Forecast for Crohn’s Disease (2016-2026)
3.6.1 Diagnosed Incident Cases of Crohn’s Disease
3.6.2 Diagnosed Prevalent Cases of Crohn’s Disease
3.7 Discussion
3.7.1 Epidemiological Forecast Insight
3.7.2 Limitations of Analysis
3.7.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for this Report
4.3 Primary Research - Prescriber Survey
4.4 About the Authors
4.4.1 Epidemiologist
4.4.2 Reviewers
4.4.3 Global Director of Therapy Analysis and Epidemiology
4.4.4 Global Head and EVP of Healthcare Operations and Strategy
4.5 About GlobalData
4.6 Contact Us
4.7 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Crohn’s Disease
Table 2: 7MM, Diagnosed Incident Cases of CD, All Ages, Both Sexes, Select Years 2016-2026
Table 3: 7MM, Diagnosed Prevalent Cases of CD, Men and Women, All Ages, Select Years 2016-2026
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of CD, Both Sexes, All Ages, 2016 and 2026 5
Figure 2: 7MM, Diagnosed Prevalent Cases of CD, Both Sexes, All Ages, 2016 and 2026 6
Figure 3: 7MM, Age-Adjusted Diagnosed Prevalence of CD (%), Men, All Ages, 2006 to 2026 10
Figure 4: 7MM, Age-Adjusted Diagnosed Prevalence (%) of CD, Women, All Ages, 2006-2026 11
Figure 5: Sources Used and Not Used, Diagnosed Incident Cases of CD 14
Figure 6: Sources Used and Not Used, Diagnosed Prevalent Cases of CD 15
Figure 7: Sources Used, Diagnosed Prevalent Cases of CD with Comorbid Autoimmune Diseases 16
Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of CD, Both Sexes, 2016 28
Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of CD, All Ages, 2016 29
Figure 10: 7MM, Diagnosed Prevalent Cases of CD by Severity, Both Sexes, All Ages, 2016 30
Figure 11: 7MM, Diagnosed Prevalent Cases of CD with Psoriasis, Ankylosing Spondylitis, and Pyoderma Gangrenosum, Both Sexes, All Ages, 2016 31
Figure 12: US and 5EU, Alternate Diagnosed Incident Cases of CD, Both Sexes, All Ages, 2016 32
Figure 13: Germany, Spain, Italy, and the UK, Alternate Diagnosed Prevalent Cases of CD, Both Sexes, All Ages, 2016 33

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report